Search Results - "Neelapu, Sattva Swarup"

A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (γδ) T cells in adults with B-cell malignancies by Neelapu, Sattva Swarup, Hamadani, Mehdi, Miklos, David Bernard, Holmes, Houston, Hinkle, John, Kennedy-Wilde, Jackie, Maller, Ori, Weinstein, Maggie, Galimi, Francesco, Lai, Rose, Stevens, Don A.

“…7509 Background: ADI-001 is a first-in-class allogeneic gamma delta (γδ) CAR T-cell therapy targeting the B-cell antigen CD20. ADI-001 also has both adaptive…”
Get full text

Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma by Steiner, Raphael Eric, Strati, Paolo, Flowers, Christopher, Neelapu, Sattva Swarup, Green, Michael Richard, Nastoupil, Loretta J., Hagemeister, Fredrick B., Feng, Lei, Ahmed, Sairah, Nair, Ranjit, Fayad, Luis, Lee, Hun Ju, Rodriguez, Maria Alma, Westin, Jason

“…TPS7589 Background: Primary mediastinal large B-cell lymphoma (PMBL) is a rare and distinct subtype of diffuse large B-cell lymphoma and affects primarily…”
Get full text

Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL) by Locke, Frederick L., Lekakis, Lazaros J., Eradat, Herbert, Munoz, Javier, Tees, Michael Timothy, de Vos, Sven, Nath, Rajneesh, Stevens, Don A., Malik, Shahbaz, Popplewell, Leslie, Hamadani, Mehdi, Oluwole, Olalekan O., Perales, Miguel-Angel, Miklos, David Bernard, Fisher, Paul, Goyal, Lovely, Kaufman, Gregory, Kai, Kazuharu, Balakumaran, Arun, Neelapu, Sattva Swarup

“…2517 Background: Approximately 50% to 60% of pts with r/r LBCL will either not achieve a complete response (CR) or will relapse with current treatments and…”
Get full text

ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM) by Manasanch, Elisabet Esteve, Korde, Neha, Lee, Hans C., Patel, Krina K., Becnel, Melody, Berrios, David, Thomas, Sheeba K., Iyer, Swaminathan Padmanabhan, Mailankody, Sham, Amini, Behrang, Lin, Pei, Berkova, Zuzana, Weber, Donna M., Feng, Lei, Neelapu, Sattva Swarup, Jagannath, Sundar, Hildebrandt, Michelle Ann Theobald, Orlowski, Robert Z., Landgren, Ola

“…8046 Background: HRSMM patients (pts) have a median time to progression of < 2 years. ISA is a monoclonal antibody that binds to highly expressed CD38 on…”
Get full text

First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study by Neelapu, Sattva Swarup, Munoz, Javier, Locke, Frederick Lundry, Miklos, David Bernard, Brown, Robert, McDevitt, Jennifer T., Mardiros, Armen, Demirhan, Eren, Konto, Cyril, Tees, Michael Timothy

“…Abstract only 8002 Background: Allogeneic (off the shelf) chimeric antigen receptor (CAR) T cell therapy addresses the logistical challenges and variable…”
Get full text

Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy by Tees, Michael Timothy, Neelapu, Sattva Swarup, Hari, Parameswaran, Mailankody, Sham, Miklos, David Bernard, Locke, Frederick Lundry, Nath, Rajneesh, Prashad, Sacha Leandra, Zhou, Xiangdong, Demirhan, Eren, Ponnathapura Nandakumar, Srinand, Fisher, Dennis, Opiteck, Gregory, Wang, Ena

“…Abstract only 2527 Background: Allogeneic chimeric antigen receptor (CAR) T cell therapy holds promise in addressing logistical/manufacturing challenges of…”
Get full text

Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL) by Chou, Justin, Plaks, Vicki, Poddar, Soumya, Wang, Zixing, Locke, Frederick Lundry, Neelapu, Sattva Swarup, Miklos, David Bernard, Jacobson, Caron A., Armand, Philippe, Bashir, Zahid, Galon, Jérôme, Rossi, John M., Bot, Adrian

“…Abstract only 7536 Background: Axi-cel is an autologous anti-CD19 CAR T-cell therapy approved for patients (pts) with relapsed/refractory LBCL after ≥2 prior…”
Get full text

First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study by Locke, Frederick Lundry, Malik, Shahbaz, Tees, Michael Timothy, Neelapu, Sattva Swarup, Popplewell, Leslie, Abramson, Jeremy S., McDevitt, Jennifer T., Shin, Chu Ri, Demirhan, Eren, Konto, Cyril, Lekakis, Lazaros J.

“…Abstract only 2529 Background: Allogeneic CAR T cell therapy addresses logistical/manufacturing challenges inherent in autologous (auto) CAR T therapy…”
Get full text

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5 by Chavez, Julio C., Jacobson, Caron A., Sehgal, Alison, Neelapu, Sattva Swarup, Maloney, David G., Salles, Gilles A., William, Basem M., Yang, Yin, Goyal, Lovely, Chou, Justin, Plaks, Vicki, Avanzi, Mauro P.

“…Abstract only 7548 Background: ZUMA-5 is a Phase 2 study of axi-cel anti-CD19 CAR T-cell therapy in pts with R/R iNHL (follicular lymphoma [FL]; marginal zone…”
Get full text

Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function by Mamlouk, Omar, Strati, Paolo, Feng, Lei, Sun, Ryan, Steiner, Raphael Eric, Nair, Ranjit, Flowers, Christopher, Ramdial, Jeremy L, Saini, Neeraj, Srour, Samer Ali, Champlin, Richard E., Kebriaei, Partow, Nastoupil, Loretta J., Rodriguez, Maria Alma, Shpall, Elizabeth J., Nieto, Yago, Westin, Jason, Neelapu, Sattva Swarup, Mandayam, Sreedhar, Ahmed, Sairah

“…7536 Background: Chimeric antigen receptor T-cell therapy (CART) is approved for treatment of relapsed and refractory large B cell lymphoma (r/r LBCL), however…”
Get full text

Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: Real-world experience from the United States lymphoma CAR T consortium by Jain, Preetesh, Wang, Yucai, Locke, Frederick L., Munoz, Javier, Beitinjaneh, Amer, Frank, Matthew Joshua, Dahiya, Saurabh, Jacobs, Miriam T., Hill, Brian T, Lekakis, Lazaros J., Miklos, David Bernard, Ghobadi, Armin, Neelapu, Sattva Swarup, Lin, Yi, Wang, Michael, Jain, Michael D., Maurer, Matthew J.

“…e19583 Background: Brexucabtagene autoleucel (BA) is an FDA approved therapy for relapsed/refractory (R/R) mantle cell lymphoma (MCL), based on results from…”
Get full text

Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma by Cherng, Hua-Jay Jeffery, Alig, Stefan, Oki, Yasuhiro, Nastoupil, Loretta J., Fayad, Luis, Neelapu, Sattva Swarup, Turturro, Francesco, Hagemeister, Frederick B., Rodriguez, Maria Alma, Lee, Hun Ju, McDonnell, Timothy, Flowers, Christopher, Vega, Francisco, Green, Michael Richard, Alizadeh, Ash A., Davis, Richard Eric, Westin, Jason

“…7553 Background: Diffuse large B-cell lymphoma (DLBCL) can be cured with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), but a…”
Get full text

Clinicopathologic features and outcomes of de novo transformed indolent lymphoma by Chin, Collin K, Cheah, Chan, Jain, Preetesh, Fowler, Nathan Hale, Fayad, Luis, Westin, Jason, Rodriguez, Maria Alma, Noorani, Mansoor, Neelapu, Sattva Swarup, Hagemeister, Fredrick B., Medeiros, L Jeffrey, Vega, Francisco, Samaniego, Felipe, Flowers, Christopher, Nastoupil, Loretta J.

“…Abstract only 8061 Background: Untreated transformed indolent lymphoma (unTIL) can present as a composite lymphoma (COM), 2 or more separate sites of disease…”
Get full text

Tumor microenvironment associated with increased pretreatment density of activated PD-1+ LAG-3+/− TIM-3− CD8+ T cells facilitates clinical response to axicabtagene ciloleucel (axi-cel) in patients (pts) with large B-cell lymphoma by Galon, Jerome, Scholler, Nathalie, Perbost, Regis, Turcan, Sarah, Danan, Corinne, Locke, Frederick Lundry, Neelapu, Sattva Swarup, Miklos, David Bernard, Jacobson, Caron A., Lekakis, Lazaros J., Lin, Yi, Ghobadi, Armin, Chou, Justin, Wang, Zixing, Xue, Allen, Rossi, John M., Bot, Adrian

“…Abstract only 3022 Background: Axi-cel is a US and EU-approved autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for pts with…”
Get full text

Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1 by Locke, Frederick Lundry, Bartlett, Nancy L., Jacobson, Caron A., Oluwole, Olalekan O., Munoz, Javier, Lekakis, Lazaros J., Topp, Max S., Avivi, Irit, Kim, Jenny J., Chu, Rong, Zheng, Lianqing, Rossi, John M., Bot, Adrian, Neelapu, Sattva Swarup

“…Abstract only 8012 Background: Axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is approved in the US and EU for pts with…”
Get full text

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20–containing chemoimmunotherapy (POD24) by Jacobson, Caron A., Chavez, Julio C., Sehgal, Alison, William, Basem M., Munoz, Javier, Salles, Gilles A., Casulo, Carla, Munshi, Pashna N., Maloney, David G., De Vos, Sven, Reshef, Ran, Leslie, Lori Ann, Yakoub-Agha, Ibrahim, Oluwole, Olalekan O., Chi Hang Fung, Henry, Plaks, Vicki, Yang, Yin, Lee, Jennifer, Avanzi, Mauro P., Neelapu, Sattva Swarup

“…Abstract only 7515 Background: POD24 is an indicator of poor survival in iNHL (Casulo & Barr. Blood. 2019). In the ZUMA-5 Phase 2 study of axi-cel anti-CD19…”
Get full text

Correlation of minimal residual disease negativity (MRD-) with prognosis in high-risk myeloma (HRM) by Kunacheewa, Chutima, Patel, Krina K., Lee, Hans Chulhee, Thomas, Sheeba K., Amini, Behrang, Srour, Samer, Bashir, Qaiser, Qazilbash, Muzaffar H., Weber, Donna M., Neelapu, Sattva Swarup, Orlowski, Robert Z., Feng, Lei, Lin, Pei, Manasanch, Elisabet Esteve

“…Abstract only 8024 Background: MRD is a standard measurement for response assessment in MM. Despite new treatments, HRM patients continue to have poor…”
Get full text

IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study by Abbas, Hussein, Alfayez, Mansour, Garcia-Manero, Guillermo, Ravandi, Farhad, Kadia, Tapan M., Dinardo, Courtney Denton, Mathews, Jairo, Flores, Wilmer, Andreeff, Michael, Kornblau, Steven Mitchell, Konopleva, Marina, Cortes, Jorge E., Neelapu, Sattva Swarup, Kantarjian, Hagop M., Davis, Richard Eric, Daver, Naval Guastad

“…Abstract only 7041 Background: Combining PD-1/PD-L1 blockade with hypomethylating agents (HMA) shows encouraging preliminary efficacy in AML, but immune…”
Get full text

ZUMA-12: A phase 2 multicenter study of axicabtagene ciloleucel (axi-cel) as a first-line therapy in patients (pts) with high-risk large B-cell lymphoma (LBCL) by Neelapu, Sattva Swarup, Chavez, Julio C., Lin, Yi, Munoz, Javier, Ujjani, Chaitra Shankar, Riedell, Peter, De Vos, Sven, Oluwole, Olalekan O., Kekre, Natasha, Yang, Yin, Goyal, Lovely, Backhouse, Kate, Milletti, Francesca, Kawashima, Jun, Herrera, Alex Francisco

“…Abstract only TPS7574 Background: Pts with LBCL who have persistent disease assessed by dynamic PET after rituximab-based induction therapy have an increased…”
Get full text

Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B-cell lymphoma (LBCL) by Neelapu, Sattva Swarup, Jacobson, Caron A., Oluwole, Olalekan O., Munoz, Javier, Deol, Abhinav, Miklos, David Bernard, Bartlett, Nancy L., Braunschweig, Ira, Jiang, Yizhou, Kim, Jenny J., Zheng, Lianqing, Rossi, John M., Locke, Frederick Lundry

“…Abstract only 7555 Background: Axi-cel is a US FDA-approved, autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy for the treatment of pts with…”
Get full text